Brolucizimab (Beovu)

Beovu (brolucizumab‑dbII) is covered for FDA‑approved neovascular (wet) AMD and specified off‑label neovascular ophthalmic conditions and is not covered for uses outside those listed indications. Coverage requires intravitreal administration by or under an ophthalmologist with documentation of diagnosis and dosing per the recommended schedule (6 mg monthly ×3, then every 8–12 weeks), and approvals are issued for 12 months.

"Beovu is indicated for the treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)."

Sign up to see full coverage criteria, indications, and limitations.